Sorted By:

Relevance


Medicare Monday: Part B and biosimilars, part 2

PhRMA  |  Blog Post

While the impact of CMS’ policy change remains to be seen, there is a risk that CMS’ reimbursement changes could have the unintended consequence of stifling innovation and patient access in this emerging market.   
http://catalyst.phrma.org/medicare-monday-part-b-and-biosmilars-part-2

Week in Review: The latest from PhRMA

PhRMA  |  Blog Post

CSRxP proposals would harm patients – New so-called “market-based proposals” to address health care costs are only a long list of new government regulations that would undermine the competitive market and give power to insurance companies to make treatment decisions for patients.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-april-29-2016

Medicines in Development for Immuno-Oncology 2017 Report

PhRMA  |  Report

The rapid pace of scientific advances has helped usher in a new era of medicine for cancer patients over the last decade.
https://www.phrma.org/medicines-in-development-immuno-oncology

PhRMA Statement on Medicare Part D

PhRMA  |  Press Release

A new paper from the Battelle Technology Partnership Practice estimates that a $20 billion annual reduction in biopharmaceutical sector revenue would result in 260,000 job losses across the U.S. economy. 
https://www.phrma.org/press-release/phrma-statement-on-medicare-part-d

Costs Are Rising for Parkinson's Disease

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/costs-are-rising-for-parkinson-s-disease

How patients with hypertension save with Medicare Part D

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/how-patients-with-hypertension-save-with-medicare-part-d

Upcoming symposium: Building Community Health & Wellbeing

PhRMA  |  Blog Post

here.
http://catalyst.phrma.org/upcoming-symposium-building-community-health-wellbeing

Alzheimer's Disease and the Path Forward

PhRMA  |  Press Release

Who:    Suzanne Corker, PhD, Professor of Behavioral Neuroscience, Emerita, Massachussetts Institute of Technology                  Neil Buckholtz, PhD, Director, Division of Neuroscience Office, National Institute on Aging                  Bill Chin, MD, Executive Vice President, Scientific & Regulatory Affairs, PhRMA;                  Howard Fillit, MD, Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation                  Maria Freire, PhD, President, Foundation of NIH;                  Tim Garnett, MD, Chief Medical Officer and Senior Vice President, Eli Lilly;                  Nicholas Kozaur, MD, Acting Clinical Team Lead at the FDA’s Division of Neurology Products;                  Eric Parker, PhD, Executive Director and Neuroscience Site Lead, MerckResearch Laboratories;                  Heather Snyder, PhD, Director, Medical and Scientific Relations, Alzheimer’s Association;                  Stevin Zorn, PhD, Executive Vice President of R&D, Lundbeck;                  And others             What:   Alzheimer’s: The Puzzle, The Partners, The Path Forward                 Sponsored by: PhRMA, the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation   When:  Wednesday, October 23, 2013, 9:00am – 5:45pm   Where:  National Academy of Sciences Building                   2102 Constitution Ave., NW                   Washington, DC 2003   *** Due to limiting seating capacity, please fill out the registration form found on http://www.phrma.org/projectcures by October 16, 2013.    
https://www.phrma.org/press-release/alzheimer-s-disease-and-the-path-forward

Innovation Spotlight: What is the Future of Health Care?

PhRMA  |  Video

The speakers also touched upon policy solutions to advance market-based reforms that promote competition and modernize the drug discovery and development process.
https://www.phrma.org

Biogen CEO George A. Scangos Becomes PhRMA Board Chairman

PhRMA  |  Press Release

“I am honored to take on this new role and to work with stakeholders across industry, government and academia to help develop creative policy solutions required to translate scientific discoveries into meaningful treatments for patients.”
https://www.phrma.org/press-release/biogen-ceo-george-a-scangos-becomes-phrma-board-chairman

PhRMA Applauds 2015 We Work For Health Champion Award Winners

PhRMA  |  Press Release

The 2015 We Work For Health Champions include: Edio Zampaglione, MD, FACOG, Vice President, Women’s Healthcare Medical Affairs, Bayer HealthCare Dinorah Williams, Executive Associate II, Bristol-Myers Squibb Chris Reddick, PhD, Vice President, Global Medical Affairs Research at Takeda Pharmaceuticals Warachal Eileen Faison, MD, Medical Director, Women’s and Men’s Health, Pfizer Jason Pelletier, Area Business Leader, Vermont, Sanofi US Dean G.
https://www.phrma.org/press-release/phrma-applauds-2015-we-work-for-health-champion-award-winners

Sara Weir

PhRMA  |  Biography

Weir has a Bachelor of Arts in Psychology and Political Leadership from Westminster College (Fulton, Missouri) and a Master of Science in Public Policy and Management from Carnegie Mellon University’s Heinz College.
https://www.phrma.org/biography/sara-weir

A shared commitment to value

PhRMA  |  Blog Post

While this point is technical, it highlights a critical limitation of the type of policy supported by Dr.
http://catalyst.phrma.org/a-shared-commitment-to-value

PhRMA Elects New Members of Board of Directors

PhRMA  |  Press Release

Peter Greenleaf is chief executive officer of Sucampo Pharmaceuticals, Inc., and a member of the company’s board of directors.
https://www.phrma.org/press-release/phrma-elects-new-members-of-board-of-directors

Ask About Adherence: New resources from The Medication Adherence Alliance

PhRMA  |  Blog Post

Sessions will focus on the use of health information technology, successes and challenges around adherence programs, the role of policy, and measurement and quality improvement, among other topics.
http://catalyst.phrma.org/ask-about-adherence-new-resources-from-the-medication-adherence-alliance

Profiles in courage: Latinos in the fight against Alzheimer’s

PhRMA  |  Blog Post

Adrian Perez, Ph.D. is a board-certified adult nurse practitioner, assistant professor at the University of Pennsylvania’s School of Nursing and chair of the National Association of Hispanic Nurses’ Public Policy Committee.
http://catalyst.phrma.org/profiles-in-courage-latinos-in-the-fight-against-alzheimers

A state-by-state look at coverage and access hurdles in 2016 exchange plans

PhRMA  |  Blog Post

Learn more about solutions for engaging and empowering consumers here.
http://catalyst.phrma.org/a-state-by-state-look-at-coverage-and-access-hurdles-in-2016-exchange-plans

New Documentary Highlights Tremendous Advances in Cancer Treatment

PhRMA  |  Blog Post

Jon Retzlaff is the managing director of science policy and government affairs at AACR.
http://catalyst.phrma.org/new-documentary-highlights-tremendous-advances-in-cancer-treatment

Special Edition Medicare Monday: More context on MedPAC’s analysis of drug costs

PhRMA  |  Blog Post

Two papers from the Altarum Institute in 2014 estimated the retail and nonretail prescription drug share of National Health Expenditures (NHE) from 2008 through 2023.
http://catalyst.phrma.org/special-edition-medicare-monday-more-context-on-medpac-s-analysis-of-drug-costs

340B Spotlight: Retail pharmacies continue to expand the 340B program

PhRMA  |  Blog Post

Given the size of the contract pharmacy program and the role of large for-profit pharmacy chains in a program designed for safety-net providers, policymakers should take a fresh look at the contract pharmacy program and its role in the 340B program and distorting the health care market more broadly.
http://catalyst.phrma.org/retail-pharmacies-continue-to-expand-the-340b-program

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

PhRMA  |  Blog Post

Despite the additional revenue generated through the 340B program, the 340B hospitals analyzed in this study did not appear to use that revenue to increase the charity care they provide to patients.
http://catalyst.phrma.org/340b-spotlight-icymi-340b-hearing-new-reports-highlight-growing-need-for-program-reform

ICYMI: The New York Times Highlights How Increasing Cost Sharing Hinders Access, Raises Other Health Care Costs

PhRMA  |  Blog Post

” “In 2012 the Congressional Budget Office changed how it assesses the budget implications of Medicare policy proposals.
http://catalyst.phrma.org/icymi-the-new-york-times-highlights-how-increasing-cost-sharing-hinders-access-raises-other-health-care-costs

Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

A New Way to Picture Progress Against Cancer:  In this guest blog, Jacqueline Ferguson, senior director of Global Oncology Corporate Affairs of Eli Lilly and Company, discusses how value in cancer treatment evolves and advocates for policies that foster the development of innovative medicines.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-august-28-2015

Clinical Trials Q&A: Income disparities

PhRMA  |  Blog Post

Dana and her husband, Dave Dornsife, a USC Trustee, are council members of the Yosemite Conservancy and support a WASH initiative, Water, Sanitation and Hygiene, in 22 countries throughout Africa through World Vision, an international humanitarian agency.
http://catalyst.phrma.org/clinical-trials-q-and-a-income-disparities

Medicare Monday: Positive impact of Part D on America’s seniors

PhRMA  |  Blog Post

Fewer Hospitalizations: Another study found that enrolling in Medicare Part D was tied to an 8 percent decrease in hospital admissions for seniors.
http://catalyst.phrma.org/medicare-monday-positive-impact-of-part-d-on-americas-seniors

You have reviewed the first 275 results out of 1101. Each page contains 25 results. You're on page 11.

prev 7 8 9 10 11 12 next